Key Highlights

  • INO shares fell 5.30% pre-market to $1.79 after a 213.75% gain at Monday's close.
  • Third-quarter results are due after the close on November 10.
  • The FDA granted Accelerated Approval to VOCERYQ in late October.

Inovio (NASDAQ:INO) shares fell 5.30% to $1.79 in pre-market today, down $0.10 from the prior close of $1.89. The stock closed Monday up $1.29, or 213.75%, on Volume of 222.12 million shares. After the close on November 2, the company announced the date of its third-quarter report and its participation in two scientific conferences.

Inovio, based in Plymouth Meeting, Pennsylvania, is a biotechnology company developing DNA medicines for HPV-related diseases, cancer and infectious diseases. Its platform pairs SynCon-engineered DNA plasmids with the proprietary CELLECTRA smart device, which delivers the plasmids into cells without lipid nanoparticles or viral vectors. It has 112 employees. In late October 2026 the FDA granted accelerated approval to VOCERYQ (INO-3107).

Third-Quarter Report and Call Scheduled for November 10

Inovio will release third-quarter 2026 financial results after the market close on November 10, 2026. It will then host a live conference call and webcast to discuss the results and provide a general Business update. The webcast will be archived for 90 days.

Two Scientific Presentations Planned in November

On November 8, Inovio will present at the Soft Bones Third International Scientific Meeting on Hypophosphatasia in New York, with a talk titled Rare Disease Protein Replacement Therapeutics: The Transformational Potential of Next-Gen DNA Medicine. On November 12, it will present INO-D001 for Hemophilia A at the World Federation of Hemophilia New Technology and Gene Therapy Workshop in Montreal. Abstracts and presentations will be added to the company's events page if available.

The stock has a 52-week range of $0.56 to $2.72 and trailing Earnings Per Share of negative $1.16.

November 8, 10 and 12 Mark the Next Dates for Inovio

Inovio shares are trading lower pre-market after a 213.75% advance on Monday. The next items to follow are the November 8 hypophosphatasia presentation, the November 10 third-quarter results and conference call, and the November 12 hemophilia presentation.